Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA1055)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 April 2025
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 28 January 2026
Suspected Cancer: recognition and referral (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 13 March 2026
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC